[Allogeneic bone marrow transplantation in chronic myeloid leukemia. The results of HLA-identical transplants in the Federal Republic of Germany].
In a multicenter study (seven University clinics) in the German Federal Republic bone marrow transplants from HLA-identical donors were performed in 177 patients (113 men, 64 women, mean age 32 [1.3-50] years) with Philadelphia chromosome-positive chronic myeloid leukaemia from 1982 to 1988. The survival rate among the 144 patients in whom the transplant had been carried out during the first chronic phase amounted to 58.4 +/- 11.4% after a median observation period of 3 years; survival rate among the 24 patients who underwent transplantation during the acceleration phase was 29.2 +/- 20.4%. All nine patients who received bone marrow transplants in the second chronic phase or during a blast crisis died during the period of observation (after median periods of 4 and 2 months, respectively). The most frequent causes of death among the group as a whole (82/177 patients) were interstitial pneumonia, acute and chronic graft versus host reactions (GVHD), recurrences and the toxic effects of previous treatment. The risk factors which significantly diminished survival rate were moderate to severe acute GVHD, chronic GVHD and age over 30 years.
Schmitz
N
N
II. Medizinische Klinik und Poliklinik der Universität Kiel.
D016025:Bone Transplantation / Q000379:methods*; D002423:Cause of Death; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005860:Germany, West / Q000453:epidemiology; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012307:Risk Factors; D014184:Transplantation, Homologous
D006680:HLA Antigens
Allogene Knochenmarktransplantation bei chronischer myeloischer Leukämie. Ergebnisse HLA-identischer Transplantationen in der Bundesrepublik Deutschland.